R&D Trends

Dotmatics, BioByte partner to speed drug candidate selection

Tuesday, April 5, 2016

Dotmatics, a provider of scientific informatics solutions and services to the life sciences industry, announced a partnership with BioByte, producer of the industry gold standard partition coefficient calculator (ClogP). This deal will enable users of the Dotmatics Platform including Vortex and Browser to calculate ClogP seamlessly within the applications. This will streamline the research process and speed up the selection of potential drug candidates.  

[Read More]

Revisiting industry partnerships with the Department of Veterans Affairs

Monday, April 4, 2016

Contract research organizations (CROs) should consider partnering with the Department of Veterans Affairs (VA) when conducting clinical trials, according to an attendee at the recent Clinical Trial Collaborations conference in Boston, Massachusetts. “The atmosphere is right for increasing the number of industry-VA collaborations,” said Dawn McKenna, executive director of the Bedford VA Research Corporation in Bedford, Massachusetts. McKenna spent years working in the pharmaceutical research and development industry as well as government and nonprofit areas before taking the helm in Bedford last year.   

[Read More]

Megafunds as an avenue to boost drug development

Monday, April 4, 2016

With skyrocketing drug development costs and increasing pressure on traditional resources, creation of private megafunds to boost drug research seems to be gaining more traction.
A recent initiative is an $866 million development fund established by Mitsui & Co., contract researcher Quintiles and other investors. The new private equity fund will invest mainly in drugs from major U.S. and European companies that are in phase III clinical trials, particularly cancer therapies and treatments for central nervous system disorders.

[Read More]

Dana-Farber, Ontario Institute join collaborative cancer cloud

Friday, April 1, 2016

The Knight Cancer Institute at Oregon Health & Science University and Intel are expanding participation in the Collaborative Cancer Cloud, a distributed precision medicine analytics platform, to include Dana-Farber Cancer Institute and Ontario Institute for Cancer Research. The institutions will join the OHSU Knight Cancer Institute in leveraging Intel’s technology to securely share and analyze their collectively large amounts of data, while preserving the privacy and security of patient data at each site.

[Read More]

Orig3n, Sharp Edge Labs ink drug discovery alliance

Monday, March 28, 2016

ORIG3N, a regenerative medicine provider, and Sharp Edge Labs, a drug discovery and development company focused on genetic disorders, have entered into a drug discovery alliance. As part of the alliance, ORIG3N will make patient-derived cells available to Sharp Edge Labs for use in their drug discovery platform for genetic disorders.

[Read More]

Paul G. Allen Frontiers Group to launch for ‘out-of-the-box’ research

Thursday, March 24, 2016

Philanthropist and entrepreneur Paul G. Allen has announced an initial commitment of $100 million to create The Paul G. Allen Frontiers Group, whose purpose will be to explore the landscape of bioscience and fund ideas at the frontier of knowledge to advance science and make the world better. As part of the launch, the Frontiers Group announces its first cohort of funded projects with four new Allen Distinguished Investigators (ADI) and two Allen Discovery Centers in partnership with Stanford University and Tufts University.

[Read More]